Status:
COMPLETED
Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
Lead Sponsor:
Regeneron Pharmaceuticals
Conditions:
Gout
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This was a clinical research study to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who were beginning another additional treatment. Partic...
Eligibility Criteria
Inclusion
- Male or female greater than 18 years of age;
- Previously met the preliminary criteria of the American Rheumatism Association (ARA) for the classification of the acute arthritis of primary gout;
- At least 2 gout flares in the year prior to the screening visit.
Exclusion
- Acute gout flare within 2 weeks of the screening visit and during screening;
- Persistent chronic or active infections;
- History of an allergic reaction to allopurinol;
- History or presence of cancer within 5 years of the screening visit.
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00610363
Start Date
November 1 2007
End Date
October 1 2008
Last Update
May 2 2017
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
San Diego, California, United States, 92108
2
Santa Maria, California, United States, 93454
3
Whittier, California, United States, 90601
4
Colorado Srings, Colorado, United States, 80910